Lizaso A - Search Results

1

Zeng L, Xu Q, Yang N, Lizaso A, Zhang Y. Zeng L, et al. Among authors: lizaso a. Thorax. 2021 May;76(5):525. doi: 10.1136/thoraxjnl-2020-216130. Epub 2020 Nov 23. Thorax. 2021. PMID: 33229403 No abstract available.

2

Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC.

Zhang Y, Zeng L, Zhou C, Li Y, Wu L, Xia C, Jiang W, Hu Y, Liao D, Xiao L, Liu L, Yang H, Xiong Y, Guan R, Lizaso A, Mansfield AS, Yang N. Zhang Y, et al. Among authors: lizaso a. J Thorac Oncol. 2020 Jun;15(6):1027-1036. doi: 10.1016/j.jtho.2020.02.007. Epub 2020 Feb 27. J Thorac Oncol. 2020. PMID: 32112982 Free article.

3

Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report.

Liu L, Lizaso A, Mao X, Yang N, Zhang Y. Liu L, et al. Among authors: lizaso a. Transl Lung Cancer Res. 2020 Feb;9(1):144-147. doi: 10.21037/tlcr.2020.01.10. Transl Lung Cancer Res. 2020. PMID: 32206561 Free PMC article.

4

A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.

Zhou Y, Jiang W, Zeng L, Mi J, Song L, Lizaso A, Mao X, Yang N, Zhang Y. Zhou Y, et al. Among authors: lizaso a. Lung Cancer. 2020 May;143:55-59. doi: 10.1016/j.lungcan.2020.03.019. Epub 2020 Mar 19. Lung Cancer. 2020. PMID: 32208297

5

Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy.

Wang Y, Yang N, Zhang Y, Li Li, Han R, Zhu M, Feng M, Chen H, Lizaso A, Qin T, Liu X, He Y. Wang Y, et al. Among authors: lizaso a. J Thorac Oncol. 2020 Aug;15(8):1369-1375. doi: 10.1016/j.jtho.2020.04.014. Epub 2020 Apr 27. J Thorac Oncol. 2020. PMID: 32353596 Free article.

6

Efficacy of Joungal in preventing febrile neutropenia induced by platinum-based doublet chemotherapy in lung cancer.

Zeng F, Li T, Xia C, Chen G, Sun Z, Guan R, Lizaso A, Mao X, Li K, Zhang Y. Zeng F, et al. Among authors: lizaso a. Ann Palliat Med. 2020 Jul;9(4):1688-1695. doi: 10.21037/apm-19-531. Epub 2020 Jun 23. Ann Palliat Med. 2020. PMID: 32648449 Free article.

7

[No title available]

[No authors listed] [No authors listed] PMID: 32675586

8

Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer.

Zeng L, Li Y, Xu Q, Jiang W, Lizaso A, Mao X, Zhang Y, Yang N, Wang Z. Zeng L, et al. Among authors: lizaso a. Onco Targets Ther. 2020 Jul 22;13:7101-7109. doi: 10.2147/OTT.S265974. eCollection 2020. Onco Targets Ther. 2020. PMID: 32801744 Free PMC article.

9

Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers.

Yang H, Zhou Z, Lin L, Yang M, Li C, Li Z, Yu X, Lizaso A, Han-Zhang H, Li B, Xiang J, Mao X, Xu Q, Zhang Y, Yang N. Yang H, et al. Among authors: lizaso a. Lung Cancer. 2020 Oct;148:113-121. doi: 10.1016/j.lungcan.2020.08.009. Epub 2020 Aug 19. Lung Cancer. 2020. PMID: 32889305

10

Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case report.

Zhou Y, Lizaso A, Mao X, Yang N, Zhang Y. Zhou Y, et al. Among authors: lizaso a. Ann Transl Med. 2020 Sep;8(17):1099. doi: 10.21037/atm-20-1007. Ann Transl Med. 2020. PMID: 33145318 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

64 results

Search Page